马来西亚慢性心力衰竭管理成本分析：多中心回顾性研究 Table 4（DOCX）

数据集获取（Figshare）

• 源站标题：Table_4_Cost analysis of chronic heart failure management in Malaysia: A multi-centred retrospective study.DOCX
• DOI：10.3389/fcvm.2022.971592.s004
• 发布日期：2022-11-02
• 文件数：1 个
• 文件总体积：19.41 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/Table_4_Cost_analysis_of_chronic_heart_failure_management_in_Malaysia_A_multi-centred_retrospective_study_DOCX/21454797

命令行下载

curl -L -o "Table_4_Cost analysis of chronic heart failure management in Malaysia: A multi-centred retrospective study.DOCX" "https://ndownloader.figshare.com/files/38071551"

文件清单

• Table_4_Cost analysis of chronic heart failure management in Malaysia: A multi-centred retrospective study.DOCX（19.41 KB）

文件总体积 19.41 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

BackgroundEstimation of the economic burden of heart failure (HF) through a complete evaluation is essential for improved treatment planning in the future. This estimation also helps in reimbursement decisions for newer HF treatments. This study aims to estimate the cost of HF treatment in Malaysia from the Ministry of Health’s perspective.
Materials and methodsA prevalence-based, bottom-up cost analysis study was conducted in three tertiary hospitals in Malaysia. Chronic HF patients who received treatment between 1 January 2016 and 31 December 2018 were included in the study. The direct cost of HF was estimated from the patients’ healthcare resource utilisation throughout a one-year follow-up period extracted from patients’ medical records. The total costs consisted of outpatient, hospitalisation, medications, laboratory tests and procedure costs, categorised according to ejection fraction (EF) and the New York Heart Association (NYHA) functional classification.
ResultsA total of 329 patients were included in the study. The mean ± standard deviation of total cost per HF patient per-year (PPPY) was USD 1,971 ± USD 1,255, of which inpatient cost accounted for 74.7% of the total cost. Medication costs (42.0%) and procedure cost (40.8%) contributed to the largest proportion of outpatient and inpatient costs. HF patients with preserved EF had the highest mean total cost of PPPY, at USD 2,410 ± USD 1,226. The mean cost PPPY of NYHA class II was USD 2,044 ± USD 1,528, the highest among all the functional classes. Patients with underlying coronary artery disease had the highest mean total cost, at USD 2,438 ± USD 1,456, compared to other comorbidities. HF patients receiving angiotensin-receptor neprilysin-inhibitor (ARNi) had significantly higher total cost of HF PPPY in comparison to patients without ARNi consumption (USD 2,439 vs. USD 1,933, p Inpatient cost was the main driver of healthcare cost for HF. Efficient strategies for preventing HF-related hospitalisation and improving HF management may potentially reduce the healthcare cost for HF treatment in Malaysia.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fcvm.2022.971592.s004（source: https://frontiersin.figshare.com/articles/dataset/Table_4_Cost_analysis_of_chronic_heart_failure_management_in_Malaysia_A_multi-centred_retrospective_study_DOCX/21454797）。